Madrigal Pharmaceuticals, Inc. (ETR:YDO1)
| Market Cap | 8.31B -24.0% |
| Revenue (ttm) | 1.26B +92.8% |
| Net Income | -136.90M |
| EPS | -6.14 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 37.47 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9 |
| Open | 363.20 |
| Previous Close | 372.00 |
| Day's Range | 363.20 - 368.10 |
| 52-Week Range | 323.10 - 488.90 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania. [Read more]
Financial Performance
In 2025, Madrigal Pharmaceuticals's revenue was $958.40 million, an increase of 432.05% compared to the previous year's $180.13 million. Losses were -$288.28 million, -38.12% less than in 2024.
Financial numbers in USD Financial StatementsNews
Madrigal Pharmaceuticals announces multi-year partnership with Sonic Incytes
Sonic Incytes Medical, developer of the Velacur, announced a multi-year partnership with Madrigal Pharmaceuticals (MDGL) to advance the assessment and risk stratification of patients with or at risk f...
Sonic Incytes Announces Multi-Year Partnership with Madrigal Pharmaceuticals to Advance Non-Invasive Liver Assessment in MASH
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $MDGL #Endocrinology--Sonic Incytes Medical Corp., developer of the Velacurâą point-of-care liver assessment platform, today announced a multi-year part...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ...
Madrigal Pharmaceuticals Transcript: Jefferies Global Healthcare Conference
Q3 sales reached $431M, with a $1.7B annualized run rate and over 55,850 patients on treatment. Management sees durable market growth and remains confident in late-2027 F4 outcomes timing while launching a larger follow-on study.
Kaplan Fox Notifies Madrigal Pharmaceuticals, Inc. (MDGL) Investors of a Securities Investigation into the Company
New York, New York--(Newsfile Corp. - November 17, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") ...
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
CONSHOHOCKEN, Pa., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor confer...
Kaplan Fox Announces a Securities Investigation into Madrigal Pharmaceuticals, Inc. (MDGL) - Investors Encouraged to Contact the Firm
New York, New York--(Newsfile Corp. - November 9, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") (...
MDGL Investors Have Opportunity to Join Madrigal Pharmaceuticals, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $MDGL--MDGL Investors Have Opportunity to Join Madrigal Pharmaceuticals, Inc. Fraud Investigation with SBS Law.
Did You Lose Money on Madrigal Pharmaceuticals, Inc. Stock? The Law Offices of Howard G.
BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G...
Lost Money on Madrigal Pharmaceuticals, Inc. Shares? The Law Offices of Frank R.
LOS ANGELES--(BUSINESS WIRE)--Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today anno...
Madrigal Pharmaceuticals announces real-world data on rezdiffra
Madrigal Pharmaceuticals (MDGL) announced results from multiple real-world studies of Rezdiffra presented at the American Association for the Study of Liver Diseases The Liver Meeting, taking place No...
Madrigal Announces New Real-World Data at AASLD 2026 Demonstrating Improvements in Liver Stiffness and Cardiometabolic Health Markers with Rezdiffra
CONSHOHOCKEN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc...
Madrigal Pharmaceuticals price target raised to $743 from $709 at Truist
Truist raised the firmâs price target on Madrigal Pharmaceuticals (MDGL) to $743 from $709 and keeps a Buy rating on the shares. The company reported a robust Q3, with leadâŠ
Madrigal Pharmaceuticals price target raised to $633 from $612 at Canaccord
Canaccord raised the firmâs price target on Madrigal Pharmaceuticals (MDGL) to $633 from $612 and keeps a Buy rating on the shares. The firm said Madrigal reported financial results andâŠ
H.C. Wainwright questions whistleblower allegations against Madrigal
H.C. Wainwright says says Madrigal Pharmaceuticals (MDGL) shares dropped 8% last night due to recent litigation activity regarding a complaint by a former employee under the whistleblower-protection p...
Madrigal discloses former employee filed whistleblower complaint
In the companyâs 10-Q quarterly regulatory filing, Madrigal Pharmaceuticals (MDGL) disclosed: âOn October 9, 2026, a former employee filed a complaint against the Company in the United States District...
Madrigal Pharmaceuticals price target raised to $760 from $725 at Citi
Citi raised the firmâs price target on Madrigal Pharmaceuticals (MDGL) to $760 from $725 and keeps a Buy rating on the shares after âanother strong quarterâ for Rezdiffra. The timingâŠ
Madrigal Pharmaceuticals Earnings Call Transcript: Q3 2026
Q3 sales rose 50% YoY to $431.3 million, with $55.4 million net income and more than 55,850 active patients. Market growth and F4c trials underpin expansion, while management expects continued investment and near-term earnings variability.
Madrigal Pharmaceuticals Earnings release: Q3 2026
Madrigal Pharmaceuticals released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Madrigal Pharmaceuticals Slides: Q3 2026
Madrigal Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
Madrigal Pharmaceuticals Quarterly report: Q3 2026
Madrigal Pharmaceuticals has published its Q3 2026 quarterly earnings report on November 3, 2026.
Madrigal Pharmaceuticals reports Q3 EPS $1.83, consensus ($1.09)
Reports Q3 revenue $431.27M, consensus $405.12M. Bill Sibold, Chief Executive Officer of Madrigal, stated: âMadrigal delivered another strong quarter, driven by continued Rezdiffra demand, deepening p...
Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates
CONSHOHOCKEN, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc...
Madrigal Pharmaceuticals management to meet with Citizens
Meeting to be held in Denver on November 5 hosted by Citizens.
Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH
Rezdiffra Âź (resmetirom) to be featured in more abstracts than any other approved or investigational MASH therapy Real-world evidence abstracts examine Rezdiffra effectiveness, tolerability and treatm...